You are here

  • Home
  • Archive
  • Volume 9, Issue 5
  • Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer

Article info

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer

Authors

  • Meenal Sinha Department Hematology/Oncology, School of Medicine, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Li Zhang Department Hematology/Oncology, School of Medicine, University of California San Francisco, San Francisco, California, USADepartment of Epidemiology and Biostatistics, School of Medicine, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Sumit Subudhi Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Division of Cancer Medicine, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Brandon Chen Department Hematology/Oncology, School of Medicine, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Jaqueline Marquez Department Hematology/Oncology, School of Medicine, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Eric V Liu Department Hematology/Oncology, School of Medicine, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Kate Allaire Department Hematology/Oncology, School of Medicine, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Alexander Cheung Department Hematology/Oncology, School of Medicine, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Sharon Ng Department Hematology/Oncology, School of Medicine, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Christopher Nguyen Department Hematology/Oncology, School of Medicine, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Terence W Friedlander Department Hematology/Oncology, School of Medicine, University of California San Francisco, San Francisco, California, USAHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Rahul Aggarwal Department Hematology/Oncology, School of Medicine, University of California San Francisco, San Francisco, California, USAHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Matthew Spitzer Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California, USADepartment of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA PubMed articlesGoogle scholar articles
  • James P Allison Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Division of Cancer Medicine, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Eric J Small Department Hematology/Oncology, School of Medicine, University of California San Francisco, San Francisco, California, USAHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Padmanee Sharma Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Division of Cancer Medicine, Houston, Texas, USAParker Institute of Cancer Immunotherapy, San Francisco, CA, USA PubMed articlesGoogle scholar articles
  • Lawrence Fong Department Hematology/Oncology, School of Medicine, University of California San Francisco, San Francisco, California, USAParker Institute of Cancer Immunotherapy, San Francisco, CA, USA PubMed articlesGoogle scholar articles

Citation

Sinha M, Zhang L, Subudhi S, et al
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer
Journal for ImmunoTherapy of Cancer 2021;9:e002254. doi: 10.1136/jitc-2020-002254
Online issue publication 
February 07, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.